Rates of Clostridioides difficile at an Urban Hospital During Initial COVID Pandemic Wave

Abstract

BackgroundDuring the first three months of the COVID 19 pandemic, our facility cared for an influx of patients. At the peak, the daily census exceeded 200 patients with COVID 19. Surveillance for healthcare acquired infections (HAIs) continued throughout this time. Despite the acuity of the patients and the frequent use of antibiotics, the rates of Clostridioides difficile lab ID (CDI) events remained relatively stable. We sought to determine the validity of this rate.MethodsTo determine if cases of CDI were missed, we compared the 3-month rate per 10,000 patient days in 2020 to the same time-period in 2019 (March, April, and May). The number of tests ordered during the two periods was also compared. Additionally, the Doctor of Pharmacy from our antibiotic stewardship team reviewed all orders for oral Vancomycin to determine if empiric CDI treatment was initiated without confirmatory testing.ResultsThe CDI rate for the 3 months in 2019 was zero compared to 0.48 per 10,000 patient days during the peak of the pandemic. The number of tests increased in the 2020 period to 17.5 per 10,000 patient days versus 15.8 in the 2019 period. Three patients received oral Vancomycin, each of whom had valid indications.ConclusionsBased on this data, CDI cases were not underreported. We speculate that the lack of an increase in CDI rates may be attributed to: Increased hand hygiene by staff – compliance increased to 91 % in 2020 compared to 83 % in 2019,enhanced attention to cleaning and high level disinfection, and Improved adherence to use of personal protective equipment.